<h4>Background and aims</h4>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve cardiovascular outcomes in obesity and heart failure and preserved ejection fraction; however, their safety and efficacy in heart failure with reduced ejection fraction (HFrEF) remain uncertain. The gene discussed is GLP1R; the disease is heart failure.